Suppr超能文献

移植后淋巴细胞增生性疾病的分子病理学

Molecular pathology of posttransplantation lymphoproliferative disorders.

作者信息

Chadburn A, Cesarman E, Knowles D M

机构信息

Department of Pathology, New York Hospital, Cornell Medical Center, New York, USA.

出版信息

Semin Diagn Pathol. 1997 Feb;14(1):15-26.

PMID:9044506
Abstract

Posttransplantation lymphoproliferative disorders (PT-LPDs) represent a heterogeneous group of Epstein-Barr virus (EBV) associated lymphoid proliferations occurring in the setting of immunosuppression associated with solid organ transplantation. Some PT-LPDs regress after a reduction in immunosuppression, whereas others progress despite aggressive therapy. Previously defined histopathologic categories do not correlate with clonality, and neither histopathology nor clonality has reliably predicted their clinical behavior. Recently, correlative clinical, morphological, and molecular genetic analysis has suggested that PT-LPDs are divisible into three distinct clinically relevant categories as follows: (1) plasmacytic hyperplasia: most commonly arise in the oropharynx or lymph nodes, are nearly always polyclonal, usually contain multiple EBV infectious events or only a minor cell population infected by a single form of EBV, and lack oncogene or tumor suppressor gene alterations; (2) polymorphic lymphoproliferative disorders: may arise in lymph nodes or extranodal sites including the gastrointestinal tract and lungs, are nearly always monoclonal based on the presence of clonal immunoglobulin gene rearrangements, usually contain a single form of EBV, and lack oncogene or tumor suppressor gene alterations; and (3) malignant lymphoma or multiple myeloma: present with widely disseminated disease frequently including the bone marrow, are monoclonal based on clonal immunoglobulin gene rearrangements, contain a single form of EBV, and contain alterations of one or more oncogenes or tumor suppressor genes (c-myc, ras, p53). Thus, proto-oncogene and tumor suppressor gene alterations appear to be associated with disease progression and an often fatal clinical outcome. Furthermore, multiple PT-LPD lesions occurring in the same individual but in multiple anatomic sites, either simultaneously or dysynchronously over time, may show distinct clonal immunoglobulin gene rearrangement patterns and evidence of infection by different forms of EBV, suggesting that each lesion represents a distinct clonal neoplasm that may show distinctive clinical behavior. Therefore, whenever possible, a biopsy of each one of the several PT-LPD lesions occurring in an individual should be obtained to derive a true assessment of the pathobiological nature and clinical aggressiveness of an individual's disease.

摘要

移植后淋巴组织增生性疾病(PT-LPDs)是一组异质性的与爱泼斯坦-巴尔病毒(EBV)相关的淋巴样增生,发生于实体器官移植相关的免疫抑制背景下。一些PT-LPDs在免疫抑制降低后消退,而另一些尽管接受积极治疗仍会进展。先前定义的组织病理学类别与克隆性无关,组织病理学和克隆性均无法可靠地预测其临床行为。最近,相关的临床、形态学和分子遗传学分析表明,PT-LPDs可分为三个不同的临床相关类别,如下所示:(1)浆细胞增生:最常见于口咽或淋巴结,几乎总是多克隆性的,通常包含多个EBV感染事件或仅一小部分细胞群体被单一形式的EBV感染,并且缺乏癌基因或肿瘤抑制基因改变;(2)多形性淋巴组织增生性疾病:可发生于淋巴结或结外部位,包括胃肠道和肺,基于克隆性免疫球蛋白基因重排几乎总是单克隆性的,通常包含单一形式的EBV,并且缺乏癌基因或肿瘤抑制基因改变;(3)恶性淋巴瘤或多发性骨髓瘤:表现为广泛播散性疾病,常累及骨髓,基于克隆性免疫球蛋白基因重排是单克隆性的,包含单一形式的EBV,并且包含一个或多个癌基因或肿瘤抑制基因(c-myc、ras、p53)的改变。因此,原癌基因和肿瘤抑制基因改变似乎与疾病进展和通常致命的临床结局相关。此外,同一个体在多个解剖部位同时或不同时间发生的多个PT-LPD病变,可能显示不同的克隆性免疫球蛋白基因重排模式以及不同形式EBV感染的证据,这表明每个病变代表一个独特的克隆性肿瘤,可能表现出独特的临床行为。因此,只要有可能,就应该对个体发生的多个PT-LPD病变中的每一个进行活检,以真正评估个体疾病的病理生物学性质和临床侵袭性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验